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Purpose: Nipple secretions are protein-rich and a potential source of breast cancer biomarkers
for breast cancer screening. Previous studies of specific proteins have shown limited correlation
with clinicopathological features. Our aim, in this pilot study, was to investigate the intra- and
interpatient protein composition of nipple secretions and the implications for their use as liquid
biopsies.
Experimental design: Matched pairs of nipple discharge/nipple aspirate fluid (NAF, n = 15)
were characterized for physicochemical properties and SDS-PAGE. Four pairs were selected
for semiquantitative proteomic profiling and trypsin-digested peptides analyzed using 2D-LC
Orbitrap Fusion MS. The resulting data were subject to bioinformatics analysis and statistical
evaluation for functional significance.
Results: A total of 1990 unique proteins were identified many of which are established cancer-
associated markers. Matched pairs shared the greatest similarity (average Pearson correlation
coefficient of 0.94), but significant variations between individuals were observed.
Conclusions and clinical relevance: This was the most complete proteomic study of nipple
discharge/nipple aspirate fluid to date providing a valuable source for biomarker discovery.
The high level of milk proteins in healthy volunteer samples compared to the cancer patients
was associatedwith galactorrhoea.Usingmatched pairs increased confidence in patient-specific
protein levels but changes relating to cancer stage require investigation of a larger cohort.
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1 Introduction
Although the number of women, aged 40 or less, diagnosed
with breast cancer is relatively low, they experience more ag-
gressive forms of the disease with poorer clinical outcome
[1, 2]. They are often at high risk due to a genetic predisposi-
tion toward the disease, of which mutations in breast cancer
type 1 susceptibility protein (BRCA1) and breast cancer type
2 susceptibility protein (BRCA2) tumor suppressive genes
are the best characterized [3]. Awareness of these variants, by
germ line genetic testing, informs the patient of the life-time
risk of susceptibility to the disease compared to the general
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Clinical Relevance
There remains an unmet need to provide high risk
premenopausal women with a regular and conve-
nient alternative to mammography (reduced accu-
racy primarily due to breast density and jeopardizing
patients with further exposure to radiation) for breast
cancer screening. Tissue biopsies provide valuable
diagnostic and prognostic information to support se-
lection of treatments once tumors have been de-
tected, and genomics has identified high penetrance
genes to indicate those women at highest risk, but
neither approach helps to detect the earliest manifes-
tations of the disease. Detection of cancer biomark-
ers in blood receivesmuch attention, but suffers from
massive dilution in circulation compared to the dis-
eased tissue of origin. Nipple discharge and nipple
aspirate fluid are naturally occurring liquids secreted
by the ducts and lobules, and hence have the po-
tential to provide important diagnostic information
regarding breast health. In this pilot study, we used
proteomics to analyze paired NAF samples, to iden-
tify the protein profiles of volunteers and patients.
The results indicate that matched pairs have similar
protein composition but there are significant differ-
ences between individuals. The data can be diagnos-
tic of breast health however a longitudinal patient
study is required to establish protein changes that
relate to cancer stage.
population, but it does not tell the patient when the disease
will occur [4].
Mammography successfully detects breast cancer in post-
menopausal women (98% sensitivity), but is less effective in
younger women due to image obfuscation by breast density
[5, 6]. Also, mammography lacks the high specificity in dif-
ferentiating between benign and malignant growths and also
between microcalcifications associated with low grade ductal
carcinoma in situ (DCIS), which may not require surgery,
and higher grade DCIS that may progress to an invasive tu-
mor [7], thereby resulting in overdiagnosis and overtreatment
[8]. Hence, the discovery of a mutation may result in elective
surgery to remove both breasts or prophylactic administra-
tion of tamoxifen, with consequential side effects before the
disease has occurred [9].
Therefore, new methods for the early detection of breast
cancer are required to support high risk younger women. The
search for diagnostic biomarkers of breast cancer has been
extensive and proteomics strategies increasingly employed as
part of the discovery process [10]. Plasma is by far the most
common biofluid used, but putative markers are massively
diluted relative to the site of origin of the cancer, thereby re-
ducing sensitivity [11]. As an alternative, we have chosen to
analyze secretions from the cells lining the ducts and lob-
ules of the breast that manifest as a spontaneous nipple dis-
charge or nipple aspirate fluid (herein collectively referred to
as NAF), collected by massage or breast pump, thereby dif-
ferentiating them from liquid biopsies obtained by lavage or
needle extraction.
NAF comprises a diverse range of biological materials
such as micronutrients (tocopherols, cholesterols, carotenes)
[12], hormones (estradiol, estrone, progesterone, and testos-
terone) [13], carbohydrate antigens (Thomsen Friedenreich
and Tn) [14], microRNA [15], and microbes [16] as well as
proteins. It has multiple advantages as a liquid biopsy for de-
tection of breast cancer: (i) premenopausal women are more
likely to produce NAF than postmenopausal women where
ductal atrophy may prevail [17], (ii) NAF expression is nonin-
vasive, causing minimal discomfort compared to breast can-
cer screening procedures [18], (iii) it enables procurement of
matched pairs of samples to provide an intraindividual com-
parison of the diseased with the healthy breast, (iv) biomark-
ers remain highly concentrated for analysis compared to
blood and urine, and (v) minimal sample preparation is re-
quired, compared to tissues, thereby excluding yield-reducing
protein extraction steps. NAF collection can be challenging,
often using microcapillaries, but recently Guthrie cards were
employed, though subsequent proteomic analysis only iden-
tified high abundance proteins [19]. NAF volumes are small,
but protein concentrations are sufficient to enable analyses
with state-of-the-art mass spectrometric techniques. A num-
ber of strategies to determine the NAF proteome coverage
have been undertaken many of which have been summa-
rized by Pavlou et al., as part of a comparison with their own
dataset of 854 proteins [20]. More recently, similar studies by
Brunoro et al. [21] and Kurono et al. [22] identified 557 and
372 proteins, respectively. Mostly these studies have focused
on optimizing protein and peptide separation using single
breast samples from each patient.
Our objective in this paper is to deal with the fundamental
definitions of NAF composition in paired samples and deter-
mine if the proteins present constitute biologically and phys-
iologically relevant information for diagnosing breast health.
2 Methods
2.1 Patients and sample collection
NAF samples were collected from breast cancer-free (de-
fined here as healthy) volunteers and breast cancer pa-
tients, who presented to Bradford Teaching Hospitals NHS
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Trust, in a prospective study between 2013 and 2016. All
participants gave written informed consent to undergo bi-
lateral nipple aspiration. The study protocol was approved
by University of Bradford’s Independent Scientific Advisory
Committee (reference: application/13/051). Ethical approval
was given by Leeds (East) Research Ethics Committee, refer-
ence 07/H1306/98+5. Before aspiration was attempted, the
nipple was initially cleansed with an alcohol pad. NAF col-
lection from cancer patients was performed under general
anesthetic by the clinical team, prior to surgery, assisted by
massaging the breast and the drop of liquid collected from
the nipple surface using a sterile pipette. After collection, the
samples were transferred to chilled, prelabeled tubes contain-
ing a freeze-dried protease inhibitor cocktail mixture (Roche
Diagnostics, Burgess Hill, UK), and frozen within 30 min of
collection. NAF from healthy volunteers (HVs) was collected
in a similarmanner but by the individuals themselves.Where
possible, NAF samples were collected from both breasts.
From a bank of 112 NAF samples (comprising 55 pairs and
57 single samples), 15 pairs were selected for study and char-
acterized for volume and color prior to further analysis (Sup-
porting Information Table 1). Samples were centrifuged to re-
move particulate matter, the protein concentration measured
using the Bradford assay and paired aliquots analyzed by
SDS-PAGE.
2.2 Proteomic analysis
An aliquot of each NAF sample was reduced, alkylated,
and digested overnight using modified sequencing grade
trypsin (see Supporting Information Materials and Meth-
ods). Digests were desalted, lyophilized, and then resus-
pended in 10 mM KH2PO4 in 25% v/v acetonitrile, 0.01%
w/v sodium azide, pH 3.0. The digests were subject to strong
cation exchange chromatography (SCX) with peptides frac-
tionated using stepwise increases in potassium chloride con-
centration. The SCX desalted fractions were desalted and
lyophilized.
2.3 Fusion orbitrap analysis
The lyophilized SCX fractions were resuspended in 0.1% FA
and analyzed in triplicate on a nano-LC UltiMate 3000 capil-
laryHPLC system coupled to anOrbitrap FusionTM TribridTM
Mass Spectrometer (see Supporting Information Materials
and Methods). Samples were applied to a C18, 300 m ×
5 mm, 5 m diameter, 100 A˚ PepMap precolumn before
transfer to a C18, 75 m × 50 cm, 2 m diameter, 100 A˚
PepMap column. A binary solvent system was used for chro-
matographic separations composed of 0.1% FA in 2% ace-
tonitrile and 0.1% FA in 100% acetonitrile. Data-dependent
acquisition using dynamic scanmanagementwas performed,
generating full MS spectra in the Orbitrap and MS/MS ac-
quisition in the ion-trap.
2.4 Data analysis
MS/MS fragment mass lists were searched using Proteome
Discoverer version 2.1 and Mascot software version 2.4
(see Supporting Information Materials and Methods). Only
Master Proteins (i.e., containing at least one unique pep-
tide) were accepted. Protein quantitation was defined as the
sum of the peak areas of the three strongest parent sig-
nals. Quantitation was normalized for cross-sample com-
parison. Pearson correlation coefficient calculated to deter-
mine gross similarities of paired samples, Student t-tests
used to identify significantly (p < 0.05) expressed pro-
teins and FunRich 2.1.2 used to compare proteomes and
identify common proteins. Database for Annotation, Vi-
sualization and Integrated Discovery (DAVID) version 6.8
was used for functional annotation [23], STRING version
10.0 for protein–protein interaction analysis [24], TMHMM
Server v. 2.0 for membrane association, the Plasma Pro-
teomeDatabase used for comparisonwith theNAFproteome,
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database to identify metabolic pathways, and the Early De-
tection Research Network (EDRN) to identify breast cancer
biomarkers.
3 Results
3.1 NAF sample characterization
Our preliminary objective was to characterize matched pairs
of NAF using basic biochemical procedures, measuring the
protein concentration and amount, and visualization by SDS-
PAGE, which has not been reported previously. NAF samples
from 100 breast cancer patients and HVs were grouped into
four clinical stages—invasive carcinoma (IC), DCIS, benign
lesions, and healthy. From these, 15 pairs (two noncancer,
two benign, one DCIS, and 10 ICs) were selected and charac-
terized for volume (varying from4 to 500L) and protein con-
centration (3–70 mg/mL (Supporting Information Table 1).
Samples were analyzed by SDS-PAGE demonstrating that,
in the majority of cases, pairs from the same individual had
similar profiles (Fig. 1A, Supporting Information Fig. 1 A–
C). Some cases exhibited a dominant serum albumin band,
suggesting a high plasma content (Fig. 1A, Case 2), while
others had a relatively low albumin presence (Fig. 1A, Cases
1, 3, and 4). Based on sample color there was no indication
of blood in the former group, no apparent correlation with
disease compared to healthy, and hence was not indicative
of tissue damage or tumor invasiveness. Four matched pairs,
a HV (Case 4, HV), a patient with benign phyllodes tumor
(Case 9, PB), a patient with DCIS (Case 10, PD) and a pa-
tient with IC (Case 12, PI) (Supporting Information Table 1),
were selected for proteomic analysis, based on similar protein
concentration and protein quantity (to minimize samples
preparation variation)
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Figure 1. (A) SDS-PAGE analysis
of matched pairs of NAF samples
from three IC patients (cases 1–3)
and one HV (case 4). N, NAF sam-
ples from normal breast; D, NAF
sample from diseased (benign,
DCIS or IC) breast. Arrow indi-
cates the position of serum al-
bumin. (B) Number of identified
protein (2 PSMs) by 2DLC MS
analysis of eight NAF samples
(four matched pairs, HV, PB, PD,
PI). Venn diagrams illustrating
(C). overlapping identities with
the data from the NAF study by
Pavlou et al [20], and D. overlap-
ping identities with the Human
Plasma Proteome database.
3.2 NAF proteomic analysis
For NAF to be a useful clinical sample it was important to es-
tablish the quality and complexity of proteomic data that can
be achieved using 2D-LC/MS separation. From 2D-LC/MS
analysis of all eight samples, a total of 1990 gene products
were identified (p < 0.05) (Supporting Information Table 2),
with an average of 1265 proteins per sample (SD ± 185)
(Fig. 1B). Prior to this study, the most complete proteomics
profile of NAF was that of Pavlou et al. [20]. Comparison with
our dataset, based on gene identity (691 entries Pavlou et al.,
and 1919 for our set, excluding immunoglobulin isoforms),
indicated an overlap of 563 proteins (Fig. 1C), however our
current study illustrated substantial progress in NAF charac-
terization identifying 1374 new proteins not previously seen
in NAF.
As plasma is by far the most commonly used and most
completely characterized liquid biopsy for diagnosing dis-
ease, including breast cancer [10], we wanted to establish if
the NAF proteome is likely to provide unique insights. The
Plasma Proteome Database comprises the collated quantita-
tive data for 10 546 proteins that have been detected in plasma
and serum using immunoassays or mass spectrometric tech-
niques (http://www.plasmaproteomedatabase.org/) [25]. A
comparison of the NAF profile with the plasma proteome
identified 1578 proteins in common (Fig. 1D), however 332
proteins (21% of the total NAF profile) were unique to NAF
indicating excellent potential to provide molecular informa-
tion specific to breast health.
Pairwise comparison of the NAF proteome complements
exhibited more than 50% likeness in composition (Support-
ing Information Fig. 2). Profiles for matched pairs from the
same individual showed the greatest similarity with 1017 of a
total of 1282 proteins, 1374/1685, 948/1350, and 1082/1382
common for HV, PB, PD, and PI pairs, respectively (Fig. 2A).
When the quantitative data (sum of the peak areas of the 3
most abundant unique peptides per protein) were included,
the bilateral pairs, again showed greatest positive correlation
(Pearson correlation coefficient values of 0.92 to 0.99) (Fig.
2B). The sample pair for the HV, however, showed the lowest
correlation with the other three cases, suggesting a unique
constitution.
3.3 NAF composition
The 567 proteins common to all eight 2D-LC analyses were
manually categorized based on location using UniProt (re-
lease 1026_07) into (i) intracellular, (ii) extracellular stroma
surrounding the breast cells, or (iii) plasma (Fig. 2C). Intra-
cellular proteins were further subdivided into cytoplasmic,
membrane-linked (i.e., containing transmembrane domain,
GPI or lipid anchors), or organelle-specific location. Of the
common proteins, 25% are normally found in plasma, 14%
function within the extracellular space, and 61% are from cell
components. Of the 346 cellular proteins, 45% are normally
found in the cytoplasm, 36% are membrane associated, 7%
lysosome, 8% endoplasmic reticulum/Golgi apparatus, 2%
mitochondrion, and 2% in the nucleus. The nuclear and mi-
tochondrial proteinswere particularly underrepresented, nor-
mally contributing 14 and 6% of the total human proteome,
respectively [26, 27].
Submission of the total NAF proteome to the TMHMM
transmembrane protein search engine identified 415 proteins
with transmembrane regions and a further 147 proteins with
GPI-anchor, N-terminal, or cys-modified lipid attachments
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Figure 2. (A) Comparison of the matched NAF protein profiles. (B) Pearson correlation coefficient for each NAF profile compared to each
other, based on median normalized log2 peak area for each protein. (C) Normal cellular localization of the 567 proteins common to all the
NAF samples. (D) NAF proteins detected in breast cancer signaling pathways, highlighted in red with KEGG user data mapping function
(http://www.genome.jp/kegg/)
were identified from UniProt. Hence, 27% of the proteins
present in NAF are normally found anchored in membranes
and consequently provide a valuable source of information
regarding cell integrity within breast tissue. Using STRING
analysis, 74 of the membrane proteins were linked to cell
adhesion (FDR 2.88 × 10−24), 50 proteins involved in glyco-
proteinmetabolism (FDR 2.88× 10−24), and 86 proteins have
receptor activity (FDR 1.04 × 10−21).
Although some are case specific, among the receptors de-
tected were those associated with cancer signaling pathways,
including epidermal growth factor receptor (EGFR), trans-
forming growth factor beta receptor type II and III, hepatocyte
growth factor receptor (HGFR), vascular endothelial growth
factor receptor (VEGFR1), mast/stem cell growth factor re-
ceptor (KIT), and receptor tyrosine-protein kinase Erbb-3 (Fig.
2D). Furthermore, 21mitogenic growth factors were detected
including pleiotrophin, macrophage colony-stimulating fac-
tor 1 (CSF1), transforming growth factor beta, and those pro-
duced by cancer-associated fibroblasts; proepidermal growth
factor (EGF), insulin-like growth factors I (IGF1) and II, and
platelet-derived growth factors C (PDGF-C) and D (Table 1).
Downstream processes activated by ligand-receptor binding,
including protein kinases and protein phosphatases that play
a role inMAPK-,NOTCH-, andWnt-signaling pathways,were
also identified.
In addition, cell adhesion proteins were common in NAF
including CEACAMs 1, 5, 6, and 8, NCAM2, BCAM, ALCAM,
ECAM,MCAM, and ICAM1, 14 cadherin/protocadherin pro-
teins, and five integrin subunits. Basement membrane pro-
teins, extracellularmatrix (ECM) proteins, and proteoglycans,
including laminins, mucins, collagens, and fibulins, which
play an important role in cell-ECM and cell–cell interac-
tions, were prevalent (see Supporting Information Table 2).
Laminins form a complex comprising a heterotrimer of al-
pha, beta, and gamma subunits linked by disulphide bridges,
constitute a key component of basement membranes and
have an essential role in the structure and function of ECM
[28]. Of the five laminin isoforms detected, alpha5, beta2, and
gamma1 were the most abundant in all NAF samples, indi-
cating the expression of the specific heterotrimer laminin-11
(or laminin-521) normally found in the glomerular basement
membrane of the kidney, in the neuromuscular synaptic
cleft and in placenta [29]. Overall NAF samples comprised
of a high proportion of proteins functioning in the tumor
C© 2017 The Authors. PROTEOMICS—Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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Table 1. Selected mitogenic factors and receptors detected in NAF samples
Gene ID Description Accession Score
Mascot
Coverage No. of
spectra
No. of unique
peptides
MW (kDa) Calc. pI Frequency Comments Detected in
plasma
Receptors
CD22 B-cell receptor
CD22
P20273 87 1.4 45 1 95.3 6.7 6 All except
HV
MS
NTRK2 BDNF/NT-3 growth
factors receptor
Q16620 988 3.9 54 3 91.9 6.5 8 MS
MET Hepatocyte growth
factor receptor
P08581 54 2.5 10 2 155.4 7.3 2 ELISA
IFNAR1 Interferon
alpha/beta
receptor 1
P17181 305 2.3 17 1 63.5 5.8 5 MS
IL1R1 Interleukin-1
receptor type 1
P14778 405 9.0 53 3 65.4 7.8 6 All except
HV
MS
IL13RA1 Interleukin-13
receptor subunit
alpha-1
P78552 278 5.2 18 2 48.7 6.0 4 MS
IL6ST Interleukin-6
receptor subunit
beta
P40189 4320 12.0 307 8 103.5 6.0 8 ELISA
IL7R Interleukin-7
receptor subunit
alpha
P16871 260 7.0 23 3 51.5 5.4 2 HV only MS
LIFR Leukemia inhibitory
factor receptor
P42702 1751 13.6 176 12 123.7 5.7 6 all except HV IA
LDLR Low-density
lipoprotein
receptor
P01130 331 6.5 23 3 95.3 5.1 6 MS
KIT Mast/stem cell
growth factor
receptor Kit
P10721 301 4.6 39 4 109.8 7.0 4 HV and PI
pairs
ELISA
PGRMC1 Membrane-
associated
progesterone
receptor
component 1
O00264 67 7.7 8 2 21.7 4.7 3 MS
NRP1 Neuropilin-1 O14786 2910 23.7 240 15 103.1 5.9 7 MS - MRM
ERBB3 Receptor
tyrosine-protein
kinase erbB-3
P21860 164 1.8 15 1 148.0 6.6 5 MS
TGFBR2 TGF-beta receptor
type-2
P37173 49 2.6 24 1 64.5 5.9 7 MS
TGFBR3 Transforming
growth factor
beta receptor
type 3
Q03167 279 9.4 26 5 93.4 5.7 2 MS
Mitogenic factors
IGF1 Insulin-like growth
factor I
P05019 35 5.1 4 1 21.8 9.7 2 IC pair only ELISA
IGF2 Insulin-like growth
factor II
P01344 31 5.0 3 1 20.1 9.3 2 ELISA
IL8 Interleukin-8 P10145 123 16.2 13 1 11.1 8.8 2 PD only CIA
IL19 Interleukin-19 Q9UHD0 155 22.0 39 3 20.4 7.7 2 HV only MS
IL34 Interleukin-34 Q6ZMJ4 358 6.6 26 1 27.5 7.2 8 Not detected
MYDGF Myeloid-derived
growth factor
Q969H8 177 15.6 14 2 18.8 6.7 4 MS
PGF Placenta growth
factor
P49763 82 19.0 30 2 24.8 8.2 6 All except
HV
ELISA
PDGFC Platelet-derived
growth factor C
Q9NRA1 1960 15.7 117 5 39.0 6.1 8 Not detected
PDGFD Platelet-derived
growth factor D
Q9GZP0 968 10.8 51 3 42.8 8.0 8 Not detected
PTN Pleiotrophin P21246 1536 23.8 92 3 18.9 9.6 8 MS
EGF Pro-epidermal
growth factor
P01133 17275 28.4 1201 25 133.9 5.9 8 MIA
TGFB1 Transforming
growth factor
beta-1
P01137 41 3.3 2 1 44.3 8.5 2 ELISA
TGFB2 Transforming
growth factor
beta-2
P61812 71 12.8 12 3 47.7 8.5 4 Not detected
TGFB3 Transforming
growth factor
beta-3
P10600 39 3.6 2 1 47.3 8.0 1 MS-MRM
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microenvironment, which are responsible for cancer cell be-
havior including proliferation, survival, adhesion, migration,
and invasion. Cancer-associated fibroblast markers (nepro-
lysin, matrix metalloproteinase 9 [MMP9], tenascin-C), mark-
ers of epithelial-mesenchymal transition, a prerequisite to
metastasis (TGF1, cadherin 1/E-cadherin, fibronectin, vi-
mentin, cytokeratin 8, and cytokeratin 18) and breast cancer
stem cell markers (CD44, CD133) were also detected in all
NAF samples.
Mannello et al. identified the importance of exploringNAF
for established biomarkers such as urokinase-dependent plas-
minogen activator (uPA) and plasminogen activator inhibitor
(PAI-I), particularly for their role in ECM turnover asso-
ciated with cancer invasiveness [30]. Our analysis of NAF
identified approximately 100 proteolytic enzymes, including
uPA, MMP9, and matrilysin, which function to modulate
stromal composition. Within this group were ten members
of the kallikrein family, including prostate specific antigen
(PSA/KLK3) (see Supporting Information Table 2). Previ-
ously, an inverse correlation of PSA levels (measured by
immunofluorometric assay) in NAF, with progressive breast
cancer (DCIS to metastatic), has been described [31, 32].
There were six proteins (kallikrein 6, ATP-binding cas-
sette sub-family Cmember 11, secretoglobin family 3Amem-
ber 1, mammaglobin-A, prolactin-inducible protein [PIP],
and mucin-like protein 1) that are most strongly expressed
in breast tissues (compared to all other tissues), and al-
though not cancer specific, may prove useful indicators
of breast health. PIP has previously been explored as a
NAF-derived biomarker of breast cancer by proteomics and
ELISA methods, and expression found to correlate with pre-
/postmenopausal status and cancer stage [33].
The National Cancer Institute has coordinated the re-
search of many institutions to accelerate the identification
and validation of early stage cancer testing and detection
(https://edrn.nci.nih.gov/). Of the 195 breast cancer pro-
teins and genes under investigation by the NCI Early De-
tection Research Network, 46 are present in NAF of which
22 were detected in all eight samples and seven were not
found in plasma (Table 2). Among the candidate biomark-
ers detected in NAF were C-C motif chemokine 28, CSF1,
EGFR, VEGFR1, VEGFA, ICAM1, KIT, HGFR, MMP9, met-
alloproteinase inhibitor 1 (TIMP1), osteopontin, and Toll-like
receptor 2.
CytochromeP450 3A4 (CYP3A4)was detected at lowabun-
dance in two NAF samples, right breast of the benign pa-
tient and left breast of the IC patient, and verified by west-
ern blotting (Supporting Information Fig. 3). CYP3A4 plays
an important role in converting tamoxifen to N-desmethyl-4-
hydroxytamoxifen, which has a 30- to 100-fold higher affinity
for estrogen receptor than tamoxifen [34]. CYP3A4,measured
by immnuohistochemistry in normal and cancer breast tis-
sue biopsies was found to be prognostic for patient response
to docetaxel [35, 36] and by activity assay and western blot
to correlate with ifosfamide activation [37]. The presence of
CYP3A4 in NAF provides a unique opportunity to screen
for patients who are most likely to respond to prophylactic
tamoxifen treatment.
3.4 Diagnostic application
One of our objectives was to understand whether analyzing
matched pairs would provide a more specific approach to
detecting disease compared to normal. SDS-PAGE showed
that most matched pairs have similar protein band patterns,
which was corroborated by the high correlation of proteomics
profiles. While some proteins were significantly different in
bilateral samples, a more extensive longitudinal study is re-
quired to determine statistically valid differences between
disease and healthy breast of an individual.
Nevertheless, the proteomic profiling of the HV (Case 1)
provided important diagnostic feedback relating to the cause
of nipple discharge. As already noted, the proteomic profiles
from Case 1 exhibited least correlation with the three disease
cases (Fig. 2B). A two-tailed Student t-test of HV, using the
average normalized sum of the three strongest peak areas
for each protein, from two breast analyses, compared to the
equivalent data for the three cancer samples, identified 331
proteins that were present at significantly different levels (p<
0.05)(Supporting Information Table 3). The proteomic signa-
ture for Case 1 indicated high levels of milk proteins. Of the
20 most abundant proteins observed by Beck et al., the most
complete proteome study of human milk to date, 17 were
also present in the top 50most abundant detected in the NAF
samples of Case 1 [38] (Fig. 3). Case 1 presented at the out-
patient clinic with a spontaneous milky pus discharge when
either nipple was squeezed. The reproductive history of the
volunteer, aged 48, indicated, she had achieved parity three
times (with the first birth at age 38). Small amounts ofmilk or
serous fluid expression can persist for months or years after
weaning, but Case 1 did not engage in breastfeeding. Fur-
ther investigation of her medical records, however, indicated
that she had been prescribed amitriptyline, for depression
and stress management, and omeprazole and lansoprazole
for gastric esophageal reflux. In rare cases, these may cause
breast tissue enlargement and nipple discharge, which is as-
sociated with galactorrhea rather than cancer [39].
4 Conclusions
In this study,NAF sampleswere collected bymanualmassage
techniques prior to surgery or when the patients presented
with a natural discharge at outclinic. Of those volunteers who
consented, the success rate in NAF expression was approxi-
mately 50%. In order to provide a suitable screen approach
for breast cancer specific biomarkers, increased success in
expression and collection will be required. Improved expres-
sion rates can be achieved with the aid of oxytocin nasal spray
[18,40] as well as application ofmanual ormechanical pumps
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Table 2. Biomarkers under investigation by the NCI Early Detection Research Network
Gene ID Description Accession Mascot
Score
No. of
spectra
No. of
unique
peptides
Plasma Case
profile
ADH5 Alcohol dehydrogenase class-3 P11766 252 25 4 MS
AKR1C2 Aldo-keto reductase family 1
member C2
P52895 612 51 4 ND
AKR1B1 Aldose reductase P15121 184 42 1 MS
ALPL Alkaline phosphatase,
tissue-nonspecific isozyme
P05186 3082 168 7 MS
ANXA1 Annexin A1 P04083 9026 362 16 MS
CDH1 Cadherin-1 P12830 10468 590 14 MS
CEACAM5 Carcinoembryonic antigen-related
cell adhesion molecule 5
P06731 1328 104 2 MS NQ
CCL28 C-C motif chemokine 28 Q9NRJ3 318 30 1 ND
MYCBP C-Myc-binding protein Q99417 25 9 2 MS
CRP C-reactive protein P02741 38 8 1 MS/ELISA
ENG Endoglin P17813 2738 196 9 MS/ELISA
EFNA5 Ephrin-A5 P52803 660 121 6 ND
EGFR Epidermal growth factor receptor P00533 132 18 3 MS/IA
STOM Erythrocyte band 7 integral
membrane protein
P27105 22404 1392 14 MS
FABP5 Fatty acid-binding protein, epidermal Q01469 554 60 4 MS
GPI Glucose-6-phosphate isomerase P06744 6832 334 11 MS
GSTM1 Glutathione S-transferase Mu 1 P09488 7599 544 7 MS
GSTM2 Glutathione S-transferase Mu 2 P28161 2427 197 6 ND
GNB4 Guanine nucleotide-binding protein
subunit beta-4
Q9HAV0 317 77 2 ND
MET Hepatocyte growth factor receptor P08581 54 10 2 MS
ITGB1 Integrin beta-1 P05556 32 7 2 MS
ICAM1 Intercellular adhesion molecule 1 P05362 5942 337 12 MS/ELISA
GLO1 Lactoylglutathione lyase Q04760 253 24 3 MS
LBP Lipopolysaccharide-binding protein P18428 15772 899 9 MS
CSF1 Macrophage colony-stimulating
factor 1
P09603 17423 1181 7 MS
KIT Mast/stem cell growth factor
receptor Kit
P10721 301 39 4 MS
MMP9 Matrix metalloproteinase-9 P14780 503 32 5 MS
TIMP1 Metalloproteinase inhibitor 1 P01033 4627 378 7 MS
NDUFA10 NADH dehydrogenase [ubiquinone]
1 alpha subcomplex subunit 10,
mitochondrial
O95299 107 7 1 MS
PVRL4 Nectin-4 Q96NY8 360 54 4 ND
SPP1 Osteopontin P10451 11049 982 13 MS/ELISA
PRDX4 Peroxiredoxin-4 Q13162 3107 334 9 MS
PDCD6IP Programmed cell death 6 interacting
protein
Q8WUM4 20305 1354 33 MS
S100A4 Protein S100-A4 P26447 33 17 1 MS
(Continued)
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Table 2. Continued
Gene ID Description Accession Mascot
Score
No. of
spectra
No. of
unique
peptides
Plasma Case
profile
RAC1 Ras-related C3 botulinum toxin
substrate 1
P63000 1097 177 5 MS
RAB13 Ras-related protein Rab-13 P51153 961 75 2 MS
RAB5A Ras-related protein Rab-5A P20339 1219 131 3 MS
SERPINB3 Serpin B3 P29508 173 18 3 MS
SSBP1 Single-stranded DNA-binding
protein, mitochondrial
Q04837 33 5 2 MS
TLR2 Toll-like receptor 2 O60603 2408 199 15 MS
RHOA Transforming protein RhoA P61586 3306 364 2 ND
TNFRSF11B Tumor necrosis factor receptor
superfamily member 11B
O00300 27 2 1 MS/ELISA
TNFRSF1A Tumor necrosis factor receptor
superfamily member 1A
P19438 107 5 1 MS/ELISA
VEGFA Vascular endothelial growth factor A P15692 69 32 1 ELISA/IA
FLT1 Vascular endothelial growth factor
receptor 1
P17948 295 58 1 ELISA
ATP6AP1 V-type proton ATPase subunit S1 Q15904 3922 202 6 MS
ND, not detected; NQ, not quantified; case profile description, see Fig. 3.
that are normally used for milk expression by mothers with
preterm infants [41].
Our aim was to determine whether NAF has the potential
to provide diagnostic value in screening for breast cancer.
The possibility of using an internal control sample from the
healthy breast for comparison with the diseased breast was
considered. The complement of proteins in matched pairs
showed strong similarity, probably due to transport through
cross-lymphatic drainage, which may make symptomatic dif-
ferentiation challenging. Conversely, single samples from
patients, where expression is poor, would be sufficient for
clinical diagnosis of disease-related biomarkers. In this re-
spect, we have identified double the number of proteins pre-
viously detected in NAF, including 300 not found in plasma
Figure 3. Representative pro-
files of milk proteins signifi-
cantly increased in the HV com-
pared to the three cancer pa-
tients (PB, PD, and PI). Quanti-
tation is defined as the ratio of
area for the specific protein rela-
tive to themedian of the area for
the protein complement. Each
value is the average of the val-
ues for the left and right breast
measurements.
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and 24% of themarkers currently part of the NCI Early Detec-
tion Research Network studying breast cancer. The current
breast cancer markers, growth factors, and receptors which
have been detected in plasma, required a number of indepen-
dent approaches (immunoassays and MS), whereas we have
the potential to develop a single quantitative, multiplexed,
target method by multiple reaction monitoring MS, utilizing
valuable NAF samples efficiently. Furthermore, the compo-
sition of NAF was dominated by proteins representative of
the basement membrane, extracellular milieu, and intersti-
tial fluid surrounding breast cells, with roles in tissue stabil-
ity, cell adhesion, and cell–cell communication. Future NAF
proteomic analysis will aim to investigate if changes in the
proteins correlates with stromal disruption and degradation
as cancer cells proliferate and migrate into the surrounding
normal tissue environment. Overall, the study has identified
many physiologically and oncologically important proteins
that warrant a more expansive study of a larger cohort of
patients and HVs.
Proteomics research was supported by Yorkshire Cancer Re-
search projects, BPP047 and B381PA. The authors would like to
thank the patients and volunteers for providing samples for this
research.
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